廣生堂(300436.SZ)獲新型肝癌靶向藥物GST-HG161核心化合物專利授權通知書
格隆匯1月17日丨廣生堂(300436.SZ)公佈,公司新型肝癌靶向藥物GST-HG161的核心化合物已通過PCT途徑申請國際專利,經國際檢索表明滿足新穎性、創造性和實用性,已申請進入中國、美國、日本、歐洲、澳大利亞、加拿大等24個國家和地區,且已獲得美國、新加坡的專利授權。
近日,公司收到關於GST-HG161核心化合物的發明專利授權通知書,專利的授權有利於公司完善知識產權保護體系,發揮自主知識產權優勢,提升核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.